
Opinion|Videos|December 4, 2023
The Future of Treatment for NSCLC With EGFR Exon 20 Insertion Mutations
Dr Sai-Hong Ou discusses the future of treatment for non-small cell lung cancer with EGFR exon 20 insertion mutations, highlighting the complexity of these mutations and the need for precision treatments.
Advertisement
Advertisement
Related to this article

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

The American Lung Association is urging Congress to pass the Clinical Trial Modernization Act, which may help advance research and care.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.

An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
2
Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung Cancer
3
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
4
When to Pause or Stop Therapy in Advanced RCC
5








